Racial disparity in the utilization of immunotherapy for advanced prostate cancer

CONCLUSION: FDA approval of Sipuleucel-T for mCRPC led to increased utilization of immunotherapy shortly thereafter, but this was mainly noted in white patients. Black patients comparatively did not exhibit increased utilization of this novel agent after 2010. Further studies are necessary to help understand barriers to access to new treatment in mCRPC and eliminate the burden of disease in minority populations."PMID:37903694 | DOI:10.1016/j.jnma.2023.09.007

Source: Journal of the National Medical Association - October 30, 2023 Category: General Medicine Authors: Ali Mouzannar Jessica Delgado Deukwoo Kwon Venkatasai S Atluri Matthew M Mason Nachiketh S Prakash Wei Zhao Bruno Nahar Sanjaya Swain Sanoj Punnen Mark L Gonzalgo Dipen J Parekh Leslie A Deane Chad R Ritch Source Type: research